Benitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) crossed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $11.22 and traded as high as $12.90. Benitec Biopharma shares last traded at $12.42, with a volume of 32,286 shares.
Wall Street Analysts Forecast Growth
BNTC has been the topic of several analyst reports. Baird R W raised shares of Benitec Biopharma to a "strong-buy" rating in a report on Thursday, December 12th. HC Wainwright reiterated a "buy" rating and set a $28.00 price target on shares of Benitec Biopharma in a research note on Friday, February 21st. Robert W. Baird started coverage on shares of Benitec Biopharma in a research note on Friday, December 13th. They issued an "outperform" rating and a $30.00 target price for the company. Finally, Guggenheim reissued a "buy" rating and set a $17.00 price target on shares of Benitec Biopharma in a research note on Tuesday, December 3rd. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $24.43.
Read Our Latest Stock Report on Benitec Biopharma
Benitec Biopharma Stock Down 1.8 %
The firm's 50 day simple moving average is $11.24 and its two-hundred day simple moving average is $10.49. The stock has a market cap of $299.23 million, a P/E ratio of -8.45 and a beta of 0.81.
Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last released its quarterly earnings data on Friday, February 14th. The biotechnology company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.19. As a group, equities analysts predict that Benitec Biopharma Inc. will post -1.48 EPS for the current year.
Insider Transactions at Benitec Biopharma
In other Benitec Biopharma news, Director Suvretta Capital Management, L purchased 27,502 shares of Benitec Biopharma stock in a transaction on Monday, December 23rd. The stock was bought at an average price of $10.98 per share, for a total transaction of $301,971.96. Following the transaction, the director now owns 7,981,725 shares of the company's stock, valued at $87,639,340.50. The trade was a 0.35 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 1.30% of the company's stock.
Institutional Trading of Benitec Biopharma
A number of large investors have recently added to or reduced their stakes in the business. Northern Trust Corp grew its holdings in Benitec Biopharma by 54.2% during the fourth quarter. Northern Trust Corp now owns 38,200 shares of the biotechnology company's stock valued at $482,000 after purchasing an additional 13,425 shares during the last quarter. Geode Capital Management LLC raised its stake in Benitec Biopharma by 31.3% during the 3rd quarter. Geode Capital Management LLC now owns 83,987 shares of the biotechnology company's stock valued at $772,000 after purchasing an additional 20,012 shares during the last quarter. Ameriprise Financial Inc. boosted its holdings in Benitec Biopharma by 138.4% in the 4th quarter. Ameriprise Financial Inc. now owns 35,476 shares of the biotechnology company's stock valued at $448,000 after purchasing an additional 20,597 shares during the period. Lion Point Capital LP increased its holdings in shares of Benitec Biopharma by 59.0% during the 4th quarter. Lion Point Capital LP now owns 62,000 shares of the biotechnology company's stock worth $783,000 after purchasing an additional 23,000 shares during the period. Finally, Acuta Capital Partners LLC acquired a new position in shares of Benitec Biopharma during the third quarter valued at about $274,000. 52.19% of the stock is currently owned by institutional investors.
Benitec Biopharma Company Profile
(
Get Free Report)
Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.
Featured Stories
Before you consider Benitec Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Benitec Biopharma wasn't on the list.
While Benitec Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
